Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus - Full Text View

Purpose

This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia. As part of the study, we collect neuroendocrine-immune data on patients with first episode, treatment naive psychosis, patients with newly diagnosed schizophrenia and normal healthy controls.

Regardless the treatment status, we collect the same neuroendocrine-immune data on the participants after 2 months.

Condition

Schizophrenia
Schizoaffective Disorder
Delusional Disorder

MedlinePlus related topics:

Diabetes Psychotic Disorders Schizophrenia

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case Control, Prospective

Official Title:	Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus

Further study details as provided by University of Pittsburgh:

Biospecimen Retention: Samples Without DNA

Biospecimen Description:

blood samples are collected, stored at minus 70 degree C and analyzed in batches.

Estimated Enrollment:	120
Study Start Date:	August 2003
Estimated Study Completion Date:	December 2008

Detailed Description:

This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia. As part of the study, we collect neuroendocrine-immune data on patients with first episode, treatment naive psychosis, patients with newly diagnosed schizophrenia and normal healthy controls.

Regardless the treatment status, we collect the same neuroendocrine-immune on the participants (patients and controls) after 2 months. Thus, our study does not control treatment. Patients take treatment in consultation with their physician. Some of them even decide not to take any medications. At the 2nd visit, we do ask them about the the medications they are taking if any.

Eligibility

Ages Eligible for Study:	14 Years to 50 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Probability Sample

Study Population

Patients with psychosis

Criteria

Inclusion Criteria:

Psychotic disorder as per DSM-IV criteria of the American Psychiatric Association

Exclusion Criteria:

Diabetes, type 1 or 2
Prominent substance abuse (i.e. psychotic symptoms attributable entirely to substance use)
Age above 50 or age below 14

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00222807

Contacts


Contact: Ripu D Jindal, MD	412 512 9516	jindalr@upmc.edu

Locations


United States, Pennsylvania
	University of Pittsburgh	Recruiting
	Pittsburgh, Pennsylvania, United States, 15213
	Contact: Richard S Guido, MD 412-383-1480 guidrs@upmc.edu
	Principal Investigator: Ripu D Jindal, MD
	Sub-Investigator: Matcheri S Keshavan, MD
	Sub-Investigator: Kevin Eklund, BSN
	Sub-Investigator: Govner Thorp, BS

Sponsors and Collaborators

University of Pittsburgh

American Association for Geriatric Psychiatry

Janssen Pharmaceuticals

Investigators


Principal Investigator:	Ripu D Jindal, MD	University of Pittsburgh

More Information

Responsible Party:	University of Pittsburgh ( Ripu Jindal, MD Clinical Assistant Professor )
Study ID Numbers:	0306110
First Received:	September 13, 2005
Last Updated:	February 21, 2008
ClinicalTrials.gov Identifier:	NCT00222807
Health Authority:	United States: Food and Drug Administration

Keywords provided by University of Pittsburgh:

schizophrenia, psychosis, type 2 diabetes mellitus

Study placed in the following topic categories:

Metabolic Diseases

Diabetes Mellitus

Endocrine System Diseases

Schizophrenia

Schizophrenia, Paranoid

Delusions

Mental Disorders

Diabetes Mellitus, Type 2

Psychotic Disorders

Endocrinopathy

Glucose Metabolism Disorders

Metabolic disorder

Schizophrenia and Disorders with Psychotic Features

Additional relevant MeSH terms:

Pathologic Processes

Disease

ClinicalTrials.gov processed this record on October 03, 2008

Sponsors and Collaborators:	University of Pittsburgh American Association for Geriatric Psychiatry Janssen Pharmaceuticals
Information provided by:	University of Pittsburgh
ClinicalTrials.gov Identifier:	NCT00222807